HANDOK Inc.

KOSE:A002390 Stock Report

Market Cap: ₩165.2b

HANDOK Past Earnings Performance

Past criteria checks 0/6

HANDOK's earnings have been declining at an average annual rate of -68.1%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 2.3% per year.

Key information

-68.1%

Earnings growth rate

-68.5%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate2.3%
Return on equity-10.8%
Net Margin-6.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is HANDOK (KRX:002390) A Risky Investment?

Oct 16
Is HANDOK (KRX:002390) A Risky Investment?

Is HANDOK (KRX:002390) Using Too Much Debt?

Jul 01
Is HANDOK (KRX:002390) Using Too Much Debt?

HANDOK Inc.'s (KRX:002390) 27% Share Price Surge Not Quite Adding Up

May 28
HANDOK Inc.'s (KRX:002390) 27% Share Price Surge Not Quite Adding Up

Is HANDOK Inc.'s (KRX:002390) 1.0% Dividend Worth Your Time?

Apr 01
Is HANDOK Inc.'s (KRX:002390) 1.0% Dividend Worth Your Time?

How Much Of HANDOK Inc. (KRX:002390) Do Insiders Own?

Mar 15
How Much Of HANDOK Inc. (KRX:002390) Do Insiders Own?

HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet

Feb 28
HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet

Did You Miss HANDOK's (KRX:002390) 21% Share Price Gain?

Feb 13
Did You Miss HANDOK's (KRX:002390) 21% Share Price Gain?

HANDOK Inc. (KRX:002390) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Jan 31
HANDOK Inc. (KRX:002390) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

We're Not So Sure You Should Rely on HANDOK's (KRX:002390) Statutory Earnings

Jan 18
We're Not So Sure You Should Rely on HANDOK's (KRX:002390) Statutory Earnings

Here's Why I Think HANDOK (KRX:002390) Might Deserve Your Attention Today

Jan 05
Here's Why I Think HANDOK (KRX:002390) Might Deserve Your Attention Today

Should HANDOK Inc. (KRX:002390) Be Part Of Your Dividend Portfolio?

Dec 23
Should HANDOK Inc. (KRX:002390) Be Part Of Your Dividend Portfolio?

What Kind Of Investors Own Most Of HANDOK Inc. (KRX:002390)?

Dec 10
What Kind Of Investors Own Most Of HANDOK Inc. (KRX:002390)?

HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet

Nov 27
HANDOK (KRX:002390) Has A Somewhat Strained Balance Sheet

Revenue & Expenses Breakdown

How HANDOK makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A002390 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24512,660-34,414121,96924,259
30 Jun 24510,847-33,498119,79023,936
31 Mar 24523,148-26,699118,17227,586
31 Dec 23522,741-28,797114,44828,672
30 Sep 23532,175-5,603112,64128,183
30 Jun 23553,5201,465112,48828,233
31 Mar 23545,0485,990110,12825,038
31 Dec 22543,75910,684110,82123,995
30 Sep 22547,5443,340110,83723,304
30 Jun 22533,912-2,796108,83623,553
31 Mar 22525,6771,736107,86723,176
31 Dec 21517,6413,295105,64422,879
30 Sep 21509,68415,001109,20623,203
30 Jun 21507,94731,457108,71322,044
31 Mar 21506,78429,556109,24321,105
31 Dec 20503,61226,960108,81620,135
30 Sep 20500,63931,426107,47518,168
30 Jun 20486,59733,993107,72418,028
31 Mar 20478,08027,508106,77219,062
31 Dec 19473,00034,929107,71119,240
30 Sep 19460,80516,348107,07420,611
30 Jun 19457,5783,897104,68020,193
31 Mar 19453,7189,409105,36920,197
31 Dec 18446,7317,990104,57121,119
30 Sep 18423,15415,959100,46421,634
30 Jun 18420,58515,988102,71023,209
31 Mar 18416,71013,192102,95323,029
31 Dec 17417,9704,869102,56522,449
30 Sep 17427,730-2,716102,45621,564
30 Jun 17414,775-8,991101,06819,977
31 Mar 17409,977-9,74798,48319,674
31 Dec 16396,134-6,45497,74518,472
30 Sep 16392,8411,72697,54317,730
30 Jun 16383,8771,31695,50018,386
31 Mar 16365,5872,40692,22917,171
31 Dec 15358,448-1,68787,80918,809
31 Dec 14348,3111,47381,80815,629
31 Dec 13327,93612,31069,57117,532

Quality Earnings: A002390 is currently unprofitable.

Growing Profit Margin: A002390 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A002390 is unprofitable, and losses have increased over the past 5 years at a rate of 68.1% per year.

Accelerating Growth: Unable to compare A002390's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A002390 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.3%).

Return on Equity

High ROE: A002390 has a negative Return on Equity (-10.78%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:04
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HANDOK Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Byung Hwa HanEugene Investment & Securities Co Ltd.
Seung-Ho LeeNH Investment & Securities Co., Ltd.
Eun Saem LeeShinhan Investment Corp.